| ID | 1175 |
| Name of the vaccine | Bexsero |
| Microbe | Bacteria |
| Disease name | Gonorrhoea |
| Name of bacteria | Neisseria gonorrhoeae |
| Type of vaccine | Recombinant |
| Nucleic acid content | Circular DNA |
| Age | 18 to 25 years |
| Description of the vaccine | 4-component Neisseria meningitidis group B vaccine (4CMenB). |
| Name of the manufacturer | University of North Carolina, Chapel Hill |
| Name of the manufacturing country | United States |
| Year of manufacture | 2020 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-negative diplococcus bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Two-doses, second dose at 5th week. |
| Mechanism of action | Induces antibodies in humans that recognize gonococcal proteins. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For serogroup B Meningococcal disease. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 30551148 |
| Clinical trial number | NCT04094883 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|